Company intelligence / Profile preview

PlusVitech

Seville, Andalusia, Spainplusvitech.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Currently conducting a Phase 2 clinical trial with PVT-1 (repurposed aprepitant) in 24 patients with non-small cell lung cancer (NSCLC) who are refractory to standard treatment. Previous first-time-in-human studies were positive, and there is clinical evidence of complete remission in different types of cancer.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules (repurposed drugs)
Industry: Biotech

Drug pipeline

1 asset

PVT-1

Unknown

Partnerships

Nanoform Finland Plc (announced April 9, 2024)

Beyond the preview

Go deeper on PlusVitech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PlusVitech.

Explore the full profile